Lifeboat Foundation

Researchers have long known that some genes can cause cancer when overactive, but exactly what happens inside the cell nucleus when the cancer grows has so far remained enigmatic. Now, researchers at Karolinska Institutet in Sweden have found a new mechanism that renders one canonical driver of cancer overactive. The findings, published in Nature Genetics, create conditions for brand new strategies to fight cancer.

One gene that is called MYC is central for normal cell growth. However, if the gene mutates and/or becomes overactive, it could lead to abnormal cell growth and cancer. It is previously known that so-called super-enhancers, large regions in the DNA that develop near cancer genes, could somehow make the MYC gene overactive.

The current study increases our understanding of how this process takes place by highlighting how environmental cues can conspire with the architecture of the cell nucleus to cause overexpression. With the help of new laboratory techniques and computer models, the researchers show how the activation of the pathway of the signal-molecule WNT charges the super-enhancer with proteins that lures the MYC gene to the cell nucleus pores. The pores are situated on the membrane of the cell nucleus and control the flow of information between the cell nucleus and the cytoplasm.

Obesity is an important issue.

The brain mechanism that enables us to maintain a constant body temperature may also be the key to rapid weight loss, a new study finds. In experiments involving mice that were given a calorie-restricted diet, scientists at Scripps Research discovered that blocking a brain receptor that normally regulates body heat resulted in significant weight reductions.

The findings will be further explored as a potential treatment approach for obesity, which the World Health Organization has called a global epidemic. Obesity affects virtually all age and socioeconomic groups—increasing risk for heart disease, stroke, diabetes, cancer and many other serious health conditions.

Continue reading “Brain receptor that regulates body heat may also help accelerate weight loss” »

Researcher Dr. Michael Lustgarten has recently published a compact and very readable review that focuses on the role of the gut microbiome and its influence on skeletal muscle mass.

The gut microbiome

Continue reading “Reviewing the Gut Microbiome’s Influence on Skeletal Muscle Mass” »

https://www.youtube.com/watch?v=J2G-Sq7iOuM

Hollie Fraser, founder of Books On The Move, worldwide book sharing movement, creative director and ideaXme literature, reading and writing ambassador interviews Matthew Newman, 2019 best Kindle book author.

Continue reading “How to Start at The Finish Line: Cancer Survivor” »

The search for youthfulness typically turns to lotions, supplements, serums and diets, but there may soon be a new option joining the fray. Rapamycin, a FDA-approved drug normally used to prevent organ rejection after transplant surgery, may also slow aging in human skin, according to a study from Drexel University College of Medicine researchers published in Geroscience.

Basic science studies have previously used the drug to slow aging in mice, flies, and worms, but the current study is the first to show an effect on aging in human tissue, specifically skin – in which signs of aging were reduced. Changes include decreases in wrinkles, reduced sagging and more even skin tone — when delivered topically to humans.

“As researchers continue to seek out the elusive ‘fountain of youth’ and ways to live longer, we’re seeing growing potential for use of this drug,” said senior author Christian Sell, PhD, an associate professor of Biochemistry and Molecular Biology at the College of Medicine. “So, we said, let’s try skin. It’s a complex organism with immune, nerve cells, stem cells – you can learn a lot about the biology of a drug and the aging process by looking at skin.”

Cyrus Biotechnology has teamed up with the Broad Institute to optimize CRISPR for use in humans. Feng Zhang, who had a hand in developing CRISPR, will serve as the Broad’s principal investigator for the collaboration.

One concern with using CRISPR-Cas9 to perform in vivo genome editing stems from the risk that the body will mount an immune response against the system. Those concerns have grown as researchers have shown that many people have antibodies against Cas9, reflecting the fact that the homologs of the protein used in genome editing systems are derived from bacteria that commonly infect people.

Cyrus, which lists Johnson & Johnson among its customers, thinks its technology can mitigate the risk of an immune reaction. That confidence reflects Cyrus’ experience of using software to identify and work around the epitopes in protein therapeutics that cause immunogenicity.

Read more

The University of Cambridge’s Dr. William Bains provides a thorough overview of extracellular cross-links in this lecture. He explains that advanced glycation end-products (AGEs) can irreversibly link proteins together, and cross-linking AGEs appear to play an important role in aging. They are particularly problematic in the cardiovascular system, where cross-links cause our arteries to stiffen with age, raising blood pressure and making a patient more likely to suffer from a heart attack or stroke. Cross-links are also implicated in complications from diabetes. Dr. Bains explains the structure and nature of cross-links, where they accumulate in the body, and even what their surprising role is in cooking. He ends by discussing a major AGE-breaking drug that has been tested on humans and touches on potential future therapies.

Visit www.sens.org/videos to view the rest of our course lecture videos.

https://www.youtube.com/watch?v=fCOODjrJhRQ&feature=share

Diagnosed with terminal lung cancer, Joe was told he had about 3 months to live. A veterinarian friend of his in western Oklahoma called him and told him about a cancer research experiment he had learned about in which a dog-deworming medicine had cured cancer in the experimental mice… and when the researcher developed cancer, she used the same medicine on herself and her glioblastoma was gone in about 12 weeks.

With nothing to lose and everything to gain, Joe ordered the veterinary product, Fenbendazole, and began taking it. He added a few other things to his regimen such as curcumin and Vitamin E, now known as the “Joe Tippens Protocol”. Three and a half months later, he went in for a scan and he was totally clear!

Continue reading “How Joe Tippens Beat Terminal Cancer with $7 Dog Medicine — Interviewed by James Templeton” »